Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma

Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma

Multiple myeloma (MM) is an incurable, malignant B cell disorder characterized by frequent relapses and a poor prognosis. Thus, new therapeutic approaches are warranted. The phosphatidylinositol-3-kinase (PI3K) pathway plays a key role in many critical cellular processes, including cell proliferatio...

Full description

Bibliographic Details
Main Authors: Kaiyan Sun, Ling Jin, Jana Karolová, Jan Vorwerk, Stephan Hailfinger, Bertram Opalka, Myroslav Zapukhlyak, Georg Lenz, Cyrus Khandanpour
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
multiple myeloma
mTOR
temsirolimus
MEK
trametinib
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/15/8/2373

Internet

https://www.mdpi.com/2072-6694/15/8/2373

Similar Items